DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-799/S-015

Daiichi Pharmaceutical Corporation
Attention: Amy S. Domanowski, Ph.D.
Vice President, Regulatory Affairs
11 Philips Parkway
Montvale, New Jersey 07645-1810

Dear Dr. Domanowski:

Please refer to your supplemental new drug application dated August 22, 2003, received August 25, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Floxin® Otic (Ofloxacin Otic Solution) 0.3%.

We acknowledge receipt of your submissions dated February 5 and February 18, 2004.

This supplemental new drug application provides for the use of a new proprietary name, FLOXIN® Otic SINGLES™, for the commercial and physician's sample single dispensing container (SDC) configurations of this product.

We completed the review of this supplemental application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text, dated February 18, 2004. The carton and the container labels should include the changes recommended to you on February 11, 2004.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the Guidance for Industry titled "Providing Regulatory Submissions in Electronic Format – NDA". Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-799/S-015". Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth

2/24/04 02:27:52 PM